Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
Prasad Sanjay Dhiwar(Rajiv Gandhi University of Health Sciences), Pujan Sasmal(Dr. Reddy's Laboratories (India)), Ganesh Prasad Shenoy, Nulgumnalli Manjunathaiah Raghavendra(Dayananda Sagar University), Abhishek Ghara(Dr. Reddy's Laboratories (United States)), Gurubasavaraja Swamy Purawarga Matada(Rajiv Gandhi University of Health Sciences), Nahid Abbas(Rajiv Gandhi University of Health Sciences), Ganesh S. Andhale, Ekta Singh(Rajiv Gandhi University of Health Sciences)
Cited by 8
Related Papers
Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer
|Journal of Biomolecular Structure and Dynamics|2021|37
DDR1 and DDR2: a review on signaling pathway and small molecule inhibitors as an anticancer agent
|Medicinal Chemistry Research|2021|35
Benzothiazole a privileged scaffold for Cutting-Edges anticancer agents: Exploring drug design, structure-activity relationship, and docking studies
|European Journal of Medicinal Chemistry|2024|32
An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review
|Journal of Biomolecular Structure and Dynamics|2023|28
An updated literature on BRAF inhibitors (2018–2023)
|Molecular Diversity|2023|24